

超越  
共同





®  
®




15                      5  
Organon    Abbott  
  
Palleon  
2    FIC

ASTRUM-005                      FDA  
EMA  
  
ADC                      IND-  
enabling

24,000L  
  
GMP                      QP  
  
2026  
144,000L




22                      32.1  
91.1%  
  
22  
9.8  
  
22  
5.2












✓	57	48				
✓			/	/	/	.....





...





/



/





/



Chester /Erdheim-

(1) AxC    AEC    -    AOC    -    ADC    SMC    Fusion Protein




糖尿病肾病, 肥胖, 痛风,  
NAFLD, 心衰等


阿尔  
斯泰

乳腺癌  
胰腺

类风湿, 胆管炎等



\* Deep Data Driven Drug Discovery (5D)



20



III



LS-SCLC III



MAA 23 EMA ES-SCLC



FDA



24 FDA BLA



III



4

18



10 KG Bio




23 14





FDA

HER2+



2022 5

150mg Top1000

85%

60mg 4 29

Top1000

35% 560 3,700


150mg/  
60mg/  
420mg/



Zercepac®

Tuzucip®

Trastucip®





JAMA  
Nature Medicine British Journal of  
Cancer



PD-1/PD-L1



~400      27      110      30%

DTP




MSI-H

100mg/10ml/




2021

PD-1/PD-L1



PD-1/PD-L1

PD-1/  
PD-L1




®




2019.02

2022.03

(RA)



%\*



®  
®  
®

2022

/

\* IQVIA CHPA



100mg/10ml/  
500mg/50ml/



30

31

III

"  
"  
"

" ASSC

"

"


"



2022 2

Getz Pharma

11



40mg/0.8ml/



30

25



III

® PD-1





®



100mg/4ml/







3 ADC  
NC18

2 ADC

Biomarker  
® GC/EC CDx

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_



	IND	I	II	III	NDA	
HLX61	HLX51 OX40	HLX10 <sup>(1)</sup> PD-1+LAG-3 +HLX26	HLX10 <sup>(1)</sup> PD-1+VEGF 1L +	HLX10 <sup>(1)</sup> PD-1 1L + ●	HLX10 <sup>(1)</sup> PD-1 1L +	PD-1 MSI-H <sup>(1)</sup>
HLX6018 GARP/TGF-	HLX13 CTLA-4	HLX10 <sup>(1)</sup> PD-1+GARP +HLX60 <sup>(2)</sup>	HLX10 <sup>(1)</sup> PD-1+EGFR +HLX07	HLX10 <sup>(1)</sup> PD-1 / +	HLX10 <sup>(1)</sup> PD-1 1L +	CD20 <sup>(12)</sup> <sup>(13)</sup>
HLX41 LIV1 ADC		HLX26 LAG-3	HLX07 <sup>(6)</sup> EGFR	HLX10 <sup>(1)</sup> + PD-1 1L	HLX02 HER2 <sup>(11)</sup> 	HER2 <sup>(11)</sup>
HLX42 EGFR ADC		HLX60 GARP	HLX22 + HER2+HER2	HLX10 <sup>(1)</sup> PD-1+VEGF 1L +		TNF- <sup>(14)</sup>
HLX43 PD-L1 ADC		HLX35 <sup>(3)</sup> EGFR x 4-1BB	HLX208 <sup>(7)</sup> BRAF V600E LCH/ECD	HLX04-O <sup>(8)</sup> VEGF 		VEGF <sup>(15)</sup>
HLX44 Nectin4 ADC		HLX301 <sup>(4)</sup> PD-L1 x TIGIT	HLX208 <sup>(7)</sup> + HLX10 <sup>(1)</sup> BRAF V600E + PD-1	HLX11 HER2 <sup>(9)</sup> 		
HLX80 STEAP1 ADC		HLX53 TIGIT		HLX14 RANKL <sup>(10)</sup> 		
HLX309 Nectin4 x 4-1BB		HLX05 EGFR <sup>(5)</sup>				
HLX314 HER2xSialidase		HLX15 CD38				
HLX17 PD-1						

(1)

(8)  
Tuzucip® Trastucip®2022 3 NMPA  
Accord/ Cipla/ Jacobson/ mAbxience/ Eurofarma/ Abbott (12)

(9) KGbio/

(2)

(10) Organon  
/ FARMA DE COLOMBIA/ Eurofarma/ Abbott (13)

(3)

Binacea (4)

Organon (11)

(5)





(14)



(6) 30  
/Getz Pharma (15)


(7)

Zercepac®  
Eurofarma









LCH/ECD MAPK

50

LCH/ECD  
BRAF V600E



LCH ECD



HLX208 LCH ECD

CDE

6

pre-NDA


LCH/ECD

(BTD)



HLX208

NSCLC mCRC






LCH/ECD

---

HLX07

II

HLX07



OX40 (clustering)

PD1/PDL1

PD1/PDL1

2022 11 IND






HLX53 H

Tiragolumab Atezolizumab



PD-1 mCRC NSCLC



First-in-Class  
IND  
TGF  
ADCC      GARP      Treg

First-in-Class  
EGFR      T      NK  
EGFR  
HLX35

HLX301  
Atezolizumab      Tiragolumab  
2



ES-SCLC

nsNSCLC



nsNSCLC Pivotal

mCRC PoC

sqNSCLC - OS Pivotal





NK cell engager    PD-1/PD-L1    AXC (XXC)    ADC T cell engager



mRNA



Deep Data Driven Drug Discovery(5D)  
Biocomputation Accelerated Molecule Design (BAMD)  
ADC payload



1-10                      0-1

1

2

3

4

5






EGFR

payload



PD1/PDL1

payload





规划总产能

5000L 144



24,000L



徐汇基地

24,000L



96,000L



松江基地



2022

( )

GMP



2019~



HLX04-O HLX11 HLX14



GMP






2023

PFS ADC  
CDMO


PAT









## RMB




2022	32.1	91.1%
BD	187.2%	
2022	23.7	104.4%



2022	26.8	79.0%
------	------	-------




BD	2022	17.3	86.1%
	2022 3	9	3.4%
	2022	5.5	2.1%
	2022	0.5	134.5%
	2022	5.4	187.2%





3,214.7	100.0%	1,682.5	100.0%	91.1%
2,675.4	83.2%	1,494.6	88.8%	79.0%
539.4	16.8%	187.8	11.2%	187.2%
(844.6)	(26.3%)	(522.7)	(31.1%)	61.6%
(1,049.3)	(32.6%)	(520.3)	(30.9%)	101.7%
(354.0)	(11.0%)	(280.6)	(16.7%)	26.2%
(1,394.5)	(43.4%)	(1,023.9)	(60.9%)	36.2%
(105.7)	(3.3%)	(84.8)	(5.0%)	24.6%
(693.9)	(21.6%)	(956.7)	(56.9%)	(27.5%)
(695.3)	(21.6%)	(984.1)	(58.5%)	(29.3%)









“ Henlius” “ ” LOGO

Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements),





可负担的创新 值得信赖的品质

Reliable Quality  
Affordable Innovation

